Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib versus abatacept in biologic-experienced rheumatoid arthritis
2016-000933-37Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2016
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Upadacitinib arm with Abatacept arm (2 arms). Primary endpoint: Change from baseline in DAS28 (CRP). Started Oct 2016; status: completed.
02
Drugs
upadacitinibabatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-000933-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000933-37.